Diagnoptics Technologies | Top Non Invasive Cardiovascular Risk Assessment Device in Europe 2025

MedTech Outlook Magazine

Diagnoptics Technologies
Bringing Metabolic Precision to the Front Lines of Care

John Mulder, Diagnoptics Technologies | Medical Tech Outlook | Top Non Invasive Cardiovascular Risk Assessment Device in EuropeJohn Mulder, CEO
Diagnoptics Technologies is elevating clinical risk assessment by measuring advanced glycation end-products (AGEs). These compounds form when sugars react with proteins and lipids, gradually accumulating in vital areas such as the heart, arteries, brain and skin. Over time, this buildup contributes to tissue damage and increases the risk of chronic conditions, including cardiovascular disease, diabetes and neurodegenerative disorders.

Studies show that everyone accumulates AGEs over time, starting at birth and continuing throughout life. Despite this, much of the clinical community remains unaware of AGEs or has a limited understanding of their role in chronic disease development and progression. Part of the issue lies in the traditional diagnostic focus on short-term biomarkers like glucose and lipid levels, which fluctuate daily and fail to reflect long-term metabolic stress.

One distinguishing feature of AGEs is their natural fluorescence. When exposed to a small amount of UV light, AGEs that have accumulated and cross-linked in tissue emit a faint fluorescent signal. Diagnoptics has transformed this biological trait into an advantage, helping clinicians detect underlying risks that may go unnoticed. Its breakthrough device, the AGE Reader, enables fast, non-invasive detection of AGE levels in human tissue, delivering results in about 30 seconds without requiring blood samples or biopsies.

“Our solution provides a simple and effective way to assess metabolic health,” says John Mulder, CEO.

While the fluorescent signal is invisible to the naked eye, the AGE Reader uses highly sensitive sensors to detect and measure it with precision. The stronger the signal, the higher the concentration of AGEs in the tissue. This capability makes it possible to visualize relationships with other biomarkers and conditions, offering medical professionals the critical advantage of early detection of metabolic stress before it progresses to disease.

AGE Reader augments standard diagnostics by highlighting unseen risks through a clear comparison of AGE levels to age-based averages. The device’s credibility rests on a firm scientific foundation. With more than 6,000 units sold globally, Diagnoptics has established a presence across both conventional and complementary medicine.

Empowering Clinicians to Close the Diagnostic Gap

As an integral part of the research community, Diagnoptics has spent years validating AGE Reader scores against biopsy-confirmed levels. Initial studies compared the device’s fluorescent signal with concentrations in biopsied tissue, demonstrating a strong correlation. A high AGE score reflects damage that has accumulated over years of metabolic imbalance. Follow-up research established a baseline of average levels by calendar age, revealing a near-linear increase. Today, investigations continue to refine the threshold at which accumulation becomes clinically significant. More than 300 peer-reviewed studies have linked elevated AGE levels to a broad spectrum of chronic diseases.

  • Our solution provides a simple and effective way to assess metabolic health


One of the most intuitive features of the AGE Reader is its visual risk graph, which simplifies complex biomarker data into an easy-to-understand format. As long as a person’s score remains at or below the average for healthy individuals, there’s no evidence of elevated risk. A significantly higher level indicates the likelihood of a developing or existing, asymptomatic chronic condition not flagged by conventional biomarkers. This straightforward graph is easy for clinicians and patients to interpret, making it a valuable tool for identifying when further diagnostic investigation may be necessary.

From Scan to Strategy in Seconds

The technology behind this insight is just as user friendly. A clinician places the patient’s arm on the device, presses a button, and the system emits a brief burst of UV light. The resulting fluorescence is analyzed, and a reading is generated by comparing the patient’s AGE level to the average for their age group. The reading becomes a valuable starting point for additional testing and deeper clinical investigation.

“No extensive training is required. If one can press a button, one can operate the device. It’s a powerful starting point for more targeted diagnostics and proactive care,” says Bart van den Berg, business development manager.

This value becomes especially clear in real-world scenarios. In one case, a 60-year-old woman with type 2 diabetes and mild hypertension appeared low-risk on paper. Her cardiovascular risk score sat at 8.8 percent, prompting her provider to maintain the current plan. Yet her AGE Reader score landed in the red zone, revealing significant metabolic stress that routine labs had missed. That single result prompted a shift in care, helping prevent future complications.

A Call to Action for Clinicians

The clinical promise here is fueling global expansion. While AGEs remain largely absent from clinical training and practice guidelines, Diagnoptics is working to change that. Its AGE Reader is certified as a medical device in many markets. It also offers a non-medical version for practitioners in alternative wellness environments, reinforcing the notion that metabolic health is relevant to everyone.

Recently, Diagnoptics launched clinical studies in Canada and the U.S. focused on validating AGEs as a biomarker for perioperative risk assessment. This study specifically targets same-day surgery settings across a wide range of procedures, where rapid, accurate preoperative evaluation is essential.

Diagnoptics’ relevance extends beyond clinical settings. In a forward-looking collaboration, Samsung integrated the technology into its Galaxy Watch (version 7), introducing AGE measurement to the consumer wearable space. This strategic move underscores the broader potential of AGE monitoring and highlights its value in everyday health management.

Backed by science and driven by a mission to shift diagnostics upstream, Diagnoptics Technologies is redefining preventive care. As the medical community recognizes the value of AGEs as a biomarker for various chronic conditions, Diagnoptics stands at the forefront, helping clinicians advance a more informed and proactive approach to patient care.

Non Invasive Cardiovascular Risk Assessment Device Info

Q1

Why is Diagnoptics Technologies recognized among Top Non-Invasive Cardiovascular Risk Assessment Device Manufacturers?

Diagnoptics Technologies has gained industry recognition through its focus on advanced diagnostic technologies designed to support cardiovascular risk evaluation without invasive procedures. The company develops medical assessment devices intended to help healthcare professionals identify cardiovascular-related risk indicators through efficient screening methods. Its emphasis on clinical usability, patient comfort and diagnostic precision distinguishes it among Non-Invasive Cardiovascular Risk Assessment Device Manufacturers serving modern healthcare environments.

Q2

How does Diagnoptics Technologies support cardiovascular risk evaluation?

Non-invasive screening and practical diagnostic workflows remain central to the company’s technology approach. Diagnoptics Technologies develops assessment devices that allow healthcare professionals to gather cardiovascular-related insights while minimizing patient discomfort and procedural complexity. Its solutions are designed to support efficient evaluations within clinical settings focused on preventive care and health monitoring. This practical methodology strengthens the company’s position within Non-Invasive Cardiovascular Risk Assessment Device Manufacturers serving healthcare providers.

Q3

What capabilities define the company’s diagnostic technology solutions?

Cardiovascular assessment devices, non-invasive diagnostic technology and healthcare screening solutions are key capabilities within the company’s operations. Diagnoptics Technologies focuses on medical technologies that support data-driven cardiovascular evaluation and preventive healthcare initiatives. Its diagnostic systems are designed to align with clinical efficiency and patient-centered assessment requirements. These capabilities help position it among Non-Invasive Cardiovascular Risk Assessment Device Manufacturers focused on modern cardiovascular diagnostics.

Q4

How does Diagnoptics Technologies maintain quality across its medical devices?

Clinical reliability and technology performance play an important role in the company’s product standards. Diagnoptics Technologies emphasizes accuracy, usability and consistent device functionality throughout its medical technology development processes. Its commitment to dependable diagnostic support allows healthcare professionals to integrate assessment tools confidently into patient evaluation workflows. This quality-focused approach reinforces its standing among Non-Invasive Cardiovascular Risk Assessment Device Manufacturers committed to healthcare innovation and clinical reliability.

Q5

What role does innovation play in the company’s healthcare technology development?

Cardiovascular diagnostics continue to evolve as healthcare systems increasingly prioritize preventive care and early risk identification. Diagnoptics Technologies responds to these changing needs through diagnostic technologies designed to support accessible and efficient cardiovascular assessment. The company’s focus on non-invasive evaluation methods and healthcare innovation helps it remain relevant within modern diagnostic environments. That forward-looking approach strengthens its reputation among Non-Invasive Cardiovascular Risk Assessment Device Manufacturers serving evolving healthcare needs.

Q6

Why is Diagnoptics Technologies relevant to current cardiovascular healthcare needs?

Healthcare providers increasingly seek diagnostic technologies that support efficient risk evaluation while improving patient experience. Diagnoptics Technologies addresses those priorities through non-invasive assessment devices designed for practical integration into healthcare workflows. Its emphasis on preventive diagnostics, patient-friendly screening and clinical efficiency allows the company to contribute meaningfully to cardiovascular healthcare initiatives. These strengths position Diagnoptics Technologies among trusted Non-Invasive Cardiovascular Risk Assessment Device Manufacturers supporting modern preventive healthcare strategies.

Top Non Invasive Cardiovascular Risk Assessment Device in Europe 2025

Company
Diagnoptics Technologies

Management
John Mulder, CEO

Description
Diagnoptics Technologies pioneered the AGE Reader, a non-invasive device that assesses cardiovascular and diabetes risk by detecting advanced glycation end products in skin tissue. This innovation provides clinicians with rapid, 12-second insights into metabolic and glycemic stress, supporting early detection and more personalized patient care.